Sector News

Novo opens ‘greenfield’ insulin plant in Russia

April 13, 2015
Life sciences
Novo Nordisk has opened a new manufacturing facility in Russia for formulation and filling of modern insulin destined for the treatment of diabetes.
 
Located at the Technopark Grabtsevo in the Kaluga region of Russia, the plant is the first and only greenfield facility for manufacturing modern insulin in the county, with environmental targets for CO² emission, water consumption and use of energy, according to the Danish drugmaker.
 
Around 10 million people in Russia are thought to have diabetes, and Novo says its move will ensure availability of high-quality modern insulins to patients. 
 
“I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,” said Kaluga Region Governor, Anatoly Artamonov.
 
Novo currently also has production sites in Denmark, Brazil, China, France and the US.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach